Interleukin enhancer-binding factor 3 (ILF3) (ILF3)

Interleukin enhancer-binding factor 3 (ILF3), specifically its 110 kDa isoform (NF110), is a multifunctional DNA- and RNA-binding protein that orchestrates gene expression through transcription, mRNA stabilization, and translation regulation [1.1.1, 1.2.3]. It forms a heterodimer with ILF2 (NF45) to regulate the expression of cytokines like interleukin-2 and is involved in the maturation of dendritic cells and the innate immune response [1.1.2, 1.3.2]. In oncology, ILF3/NF110 is frequently overexpressed and acts as an oncogene by promoting the expression of survivin (BIRC5) and other pro-survival factors, making it a significant driver of tumor progression and drug resistance [1.3.1, 1.4.1]. It has been identified as the primary molecular target of the small molecule suppressant YM155 (Sepantronium bromide), which binds to the C-terminal region of NF110 to inhibit survivin promoter activity [1.3.1, 1.4.2]. Beyond cancer, ILF3 is implicated in the replication of various viruses, including HIV-1 and Dengue virus, and plays a role in metabolic conditions such as non-alcoholic fatty liver disease (NAFLD) by modulating the AMPK signaling pathway [1.1.1, 1.2.1]. Therapeutic targeting of ILF3/NF110 presents challenges due to its broad biological roles in RNA metabolism and its essential function in processes like skeletal muscle development [1.3.5].

Other names

NF110NF90DRBP76NFARNFAR-2MPP4MPHOSPH4TCP80TCP110Nuclear factor of activated T-cells 90 kDaNuclear factor of activated T-cells 110 kDaM-phase phosphoprotein 4

Suppression of survivin (BIRC5) expression via direct binding to the C-terminal region of NF110 [1.3.1, 1.4.1]; Inhibition of mRNA stabilization for pro-proliferative genes [1.1.1, 1.2.1]; Modulation of the PI3K/AKT and AMPK signaling pathways [1.1.1]